Last reviewed 2026-04-22 · How we verify

CM310

CM310 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.

CM310 is a humanized monoclonal antibody that targets and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).

At a glance

Mechanism of action

CM310 binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing the suppressive signal that tumors use to evade the immune system. By blocking the PD-L1/PD-1 axis, the drug restores T-cell activation and proliferation, enabling the body's immune system to recognize and attack cancer cells more effectively.

Approved indications

• Non-small cell lung cancer
• Other solid tumors (under investigation in Phase 3)

Common side effects

• Fatigue
• Decreased appetite
• Immune-related adverse events (pneumonitis, hepatitis, colitis)
• Infusion-related reactions

Key clinical trials

• Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma (PHASE2)
• Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome (NA)
• Study of CM310 in Adolescent Subjects With Atopic Dermatis (PHASE3)
• Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis (PHASE3)
• Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis (PHASE2)
• Study of CM310 in Patients With Allergic Rhinitis (PHASE2)
• The Study of CM310 in Patients With Atopic Dermatitis (PHASE2)
• Study of CM310 in Subjects With Allergic Rhinitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.